US EditionPublished • loading... • Updated
Novartis to acquire Avidity Biosciences for about $12 billion
Novartis offers a 46% premium for Avidity Biosciences to enhance RNA therapeutics and expects to boost sales growth from 5% to 6%, with SpinCo separating early cardiology assets.
- On October 26, 2025, Novartis AG announced it will acquire all outstanding shares of Avidity Biosciences for USD 72.00 per share, valuing the company at approximately 12.0 billion.
- Novartis AG says the deal advances its xRNA and neuroscience strategy by adding Avidity’s Antibody Oligonucleotide Conjugates platform, expecting to raise its 2024-2029 sales CAGR from +5% to +6%.
- Prior to closing, Avidity will spin off its cardiology assets into SpinCo, capitalized with $270 million and led by Kathleen Gallagher as CEO and Sarah Boyce as chair; Avidity shareholders will receive SpinCo shares.
- The companies expect the merger to close in the first half of 2026, subject to regulatory approvals and Avidity stockholder approval, while Novartis and Avidity will operate independently until closing with planned product launches before 2030.
- The press release cautioned that the announcement contains forward-looking statements and warns of risks including regulatory delays, SpinCo separation issues, competing offers, and R&D uncertainties.
Insights by Ground AI
73 Articles
73 Articles
The agreement should be concluded in the first half of 2026 and followed by the separation of the early Avidity cardiology programmes into a new company.
·Portugal
Read Full Article
Novartis to acquire Avidity Biosciences for about $12B
Swiss drugmaker Novartis on Sunday said it agreed to acquire US biotech firm Avidity Biosciences for about $12 billion in cash, as the company looks to bolster its portfolio of treatments for rare muscle disorders.
·New York, United States
Read Full Article
The Swiss pharmaceutical giant Novartis announced this Sunday that he has reached an agreement to acquire Avidity Biosciences, a biopharmaceutical company based in San Diego...
·Madrid, Spain
Read Full Article
Coverage Details
Total News Sources73
Leaning Left10Leaning Right10Center17Last UpdatedBias Distribution46% Center
Bias Distribution
- 46% of the sources are Center
46% Center
L 27%
C 46%
R 27%
Factuality
To view factuality data please Upgrade to Premium
